Samjin has challenged Janssen's patent for the treatment of pulmonary arterial hypertension (Micronized Macitentan).

In the past, generic companies have challenged Opsumit patents in all directions, but it has resulted in failure, drawing keen attention to the success of Samjin's challenge.

According to the pharmaceutical industry on the 26th, Samjin recently filed a request against Janssen Korea for a passive confirmation of the scope of rights for the Opsumit patent. Opsumit is currently protected by two patents. It is material patent that expires in March 2023 and a pharmaceutical patent that expires in October 2027.

Among them, Samjin's strategy is to avoid the patent f